Wedbush Morgan Reiterates an 'Outperform' HeartWare International (HTWR); Raises PT
More News related to HTWR
- HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
- Canaccord Adams Reiterates a 'Buy' on HeartWare International (HTWR); Raises PT & Estimates
- HeartWare to Present at Upcoming Investment Conferences in November
- HeartWare International Reports Third Quarter Revenues of $7.5 Million
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
Wedbush Morgan reiterates an 'Outperform' HeartWare International, Inc. (Nasdaq: HTWR), price target increases from $32 to $40.
To see more analyst ratings on HTWR Click Here.
HeartWare International, Inc., a medical device company, focuses on developing and commercializing a family of blood pumps that are surgically implanted to help augment blood circulation in patients suffering from chronic and end-stage heart failure.
Related Categories
Analyst CommentsStocks Mentioned
-0.58Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
